We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current ABG market cap is 41B. The company's latest EPS is USD 8.7505 and P/E is 9.64.
| Year End September 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 179.59B | 189.9B | 213.99B | 238.59B | 262.2B |
| Operating Income | 1.7B | -4.77B | -3.97B | 2.37B | 2.34B |
| Net Income | 855.37M | -3.41B | -4.8B | 1.7B | 1.75B |
| Year End September 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 39.17B | 44.27B | 57.34B | 56.56B | 62.56B |
| Total Liabilities | 36.18B | 45.11B | 56.75B | 56.49B | 61.89B |
| Total Equity | 2.99B | -839.64M | 584.41M | 71.27M | 666.29M |
| Year End September 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 2.34B | 2.21B | 2.67B | 2.7B | 3.91B |
| Investing | -375.83M | -379.87M | -6.14B | -368.44M | -2.6B |
| Financing | -1.09B | -603.62M | 1.95B | -1.75B | -2.22B |
| Market Cap | 41B |
| Price to Earnings Ratio | 9.64 |
| Price to Sales Ratio | 0.06 |
| Price to Cash Ratio | 6.49 |
| Price to Book Ratio | 25.25 |
| Dividend Yield | - |
| Shares Outstanding | 199.45M |
| Average Volume (1 week) | 60 |
| Average Volume (1 Month) | 33 |
| 52 Week Change | 25.80% |
| 52 Week High | 228.50 |
| 52 Week Low | 159.42 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Cencora Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.amerisourcebergen.com |
| Industry | drugs and proprietary-whsl (5122) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
